MOG and myeloid sarcoma: Mice received 1.25 μg methotrexate per day delivered by osmotic pumps, a dosage that was protective in active MOG-induced EAE of C57Bl/6 mice and correlated with the low dose ITMTX administration in progressive MS patients (Sadiq et al., 2010).